

Acute and Subacute Ischemia of Lower Limbs: Angiography and Peripheral Hemodynamics.
Bulvas M, Sommerová Z.

Acute and Subacute Ischemia of Lower Limbs: Angiography and Peripheral Hemodynamics

Running title: Acute and subacute limb ischemia

Miroslav Bulvas, MD. PhD. Assoc. Prof.
Zuzana Sommerová, MD. PhD.

Affiliations:

Miroslav Bulvas, Department of Surgery, Division of Angiology, University Hospital
Královské Vinohrady, Third Faculty of Medicine, Charles University (address: Šrobárova 50,
100 34, Prague 10, Czech Republic)

Zuzana Sommerová, Center for Cardiovascular Prevention, First Faculty of Medicine and
Thomayer Hospital, Charles University (address: Vídeňská 800, 140 59 Prague 4, Czech
Republic), email: zuzanasommerova@mybox.cz

Corresponding author: Miroslav Bulvas, email: bulvasm@seznam.cz

miroslav.bulvas@lf3.cuni.cz

phone: +420 603426473

address: U Michelského mlýna 35, 140 00 Prague 4,
Czech Republic

ORCID iD: 0000-0003-4211-6696

Acknowledgments

The authors thank Candance McClure (NAMSA, Toledo, OH, USA) and Marian
Rybář (MATSTAT, Prague, Czech Republic) for statistical expertise.

Declaration of Conflicting Interests: The authors have no potential conflicts of interest with
respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or
publication of this article.

44 ABSTRACT

45

46 **Objective:** To identify pretreatment characteristics related to ischemia severity and symptoms
47 duration in patients with acute (ALI) and subacute lower limb ischemia (SLI).

48 **Methods:** Comparative study, a part of prospective, single-arm, single-center trial of 316
49 consecutive patients with threatened extremities (all-comers, mean age: 70.9±12.0 years,
50 range: 23-96; 184 men) of whom 99.4 % suffered from acute or subacute supratibial
51 occlusions (target occlusions).

52 **Results:** Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented
53 in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The
54 value of ABI related to the number of occluded tibial arteries. Occlusion locations associated
55 with ALI (IIA+IIB) were the aortoiliac segment and/or profunda femoris. Furthermore, ALI
56 subjects presented additional infrapopliteal occlusion (acute and/or subacute), smaller number
57 of patent tibial arteries and lower ABI.

58 Conclusion:

59 Anatomically, the most important factor related to the ischemia severity and symptoms
60 duration was the status of infrapopliteal vascular bed. The number of acutely, subacutely or
61 chronically occluded tibial vessels was related to clinical categories of ALI and SLI and to
62 ABI. This suggests that tibial reperfusion can be essential for the salvage of threatened limb
63 and should be always considered.

64

65

66

67

68

69

70

71 INTRODUCTION

72 Acute lower limb ischemia (ALI) is a critical vascular emergency that endangers the
73 affected extremity and puts the patient's life at risk. It is defined as a sudden decrease in or
74 worsening of limb perfusion that has been present for 14 days or less and causing a potential
75 threat to limb viability^{1,2}.

76 The clinical presentation of ALI is not single and varies from viable to irreversibly
77 damaged extremity. The limb can be threatened immediately after the symptoms origin or
78 later when ischemia progresses, steadily or in steps. The fact that suddenly developed
79 ischemia can escalate during the time period longer than 2 weeks, led many authors to use
80 the term "subacute limb ischemia" (SLI) to distinguish the unstable and developing condition
81 from the chronic, stable ischemic status. The guidelines^{3,4} defined SLI by symptoms duration
82 longer than 14 days, and lasting up to 3 months.

83 The pre-treatment factors, reported in the literature^{5,6} to influence the mortality and
84 amputation rates were high age, female gender, non-Caucasian race, comorbidities (diabetes,
85 malignancy, neurological disorders, coronary heart disease, congestive heart disease),
86 multilevel occlusion, more proximal occlusions, limb ischaemia severity, treatment risk and
87 urgency, tissue damage, repeated ALI attacks, absence of early anticoagulation and delay in
88 diagnosis and revascularization. However, their role and incidence may differ in patients with
89 different clinical presentation.

90 Because the same initial treatment techniques (open surgery, catheter-directed
91 thrombolysis, mechanical thrombectomy) are used in patients with ALI or SLI⁷, different
92 number of patients with SLI and those with ALI categorized as type I (viable extremity), IIA
93 (marginally threatened) or IIB (immediately threatened) have been often grouped in ALI
94 cohorts in studies to date analyzing surgical and/or endovascular treatment outcomes. To
95 understand whether such a grouping can affect the overall results and comparability among
96 the studies, it is important to learn more about characteristic of individual clinical categories.

97 Closer knowledge is necessary for better understanding the high mortality and amputation
98 rates, and the factors associated with or responsible for clinical presentation, serious events
99 and technical failure of therapeutic intervention.

100 The aim of this study was to identify the relations of ischemia severity and/or
101 symptoms duration with age, gender, comorbidities, clinical presentation, arterial occlusion
102 aetiology, vascular anatomy and peripheral hemodynamics in patients with threatened lower
103 extremity due to ALI (IIA, IIB) or SLI. Specifically, we focused on the role of infrapopliteal
104 arterial patency in 316 patients (all-comers) of whom 99.4 % primarily suffered from acute
105 or subacute supratibial occlusions (target occlusions).

106 MATERIAL AND METHODS

107 Our study was a single-centre, prospective, single-arm trial performed during the time
108 interval 2009–2015 with two main goals. The first part documented the efficacy, safety and
109 applicability of endovascular removal of occlusive material as the initial treatment in patients
110 with limb threatening ALI and SLI. It was already published⁸.

111 In this report, we focused on pre-treatment difference between clinical categories (ALI
112 vs. SLI, ALI IIB vs. ALI IIA, females vs. males, thrombotic occlusion vs. embolism). We
113 compared demographic data, frequencies of risk factors and comorbidities, clinical data,
114 ankle-brachial pressure index (ABI) and vascular anatomy characteristics (Table 1, 2).

115 The target lesion and vascular anatomy information was obtained by digital
116 subtraction angiography in all patients. No therapeutic interventions were performed or tested
117 in this part of the study.

118 The study included 316 consecutive patients (all-comers, 184 men, mean age: $70.9 \pm$
119 12.0 years): 202 subjects with ALI (114 men, mean age: 72.6 ± 12.2 , mean symptoms
120 duration: 4.13 ± 4.47 days; 146 patients categorized as IIB of the Rutherford classification for
121 acute limb ischaemia²; 56 patients of the category IIA) and 114 patients with SLI (70 men,

mean age: 67.9 ± 10.9 years; mean symptoms duration: 44.3 ± 27.3 days). SLI patients were categorized on the basis of the Rutherford classification for chronic limb ischemia² (38 patients: category 3; 50 patients: category 4; 26 patients: category 5). Critical limb ischemia was diagnosed in 74 patients with SLI according to established guidelines^{1,9,10}.

Target, supratibial occlusions (acute or subacute) were located in aortoiliac arterial segment, femoropopliteal segment, deep femoral artery, bypasses (aortofemoral, femoropopliteal, femorofemoral) and leg of bifurcation stentgraft (Table 2) in 99.4 % of patients. Isolated infrapopliteal occlusions were detected in two patients (0.6 %).

Occlusion cause was determined on the basis of clinical manifestation, angiographic findings¹¹, resistance to guidewire penetration and occurrence of underlying lesion after the clot removal. Thrombotic occlusion was diagnosed in 256 (81.0 %), and embolism in 60 (19.0 %) patients.

The University Hospital Královské Vinohrady and the Third Medical Faculty of the Charles University Centralized Institutional Review Board approved the study protocol and informed consent form (identifier: EK/IV-2/2009). The study was conducted in accordance with Declaration of Helsinki, and all patients provided written informed consent. The trial was registered with the International Standard Randomized Controlled Trials Number registry (ISRCTN 154967770). The inclusion criteria allowed enrolment of adult patients with ALI (symptoms duration ≤ 14 days) or SLI (symptoms duration >14 days and ≤ 3 months), severe claudication, ischemic rest pain, sensorimotor deficit and/or tissue defects. Patients presented from a variety of sources – overflow from other urban institutions, remote community hospitals, physician referral, and self-presenting. The exclusion criteria were irreversible ischemia and viable extremity.

Statistical analysis: continuous data are presented as the mean \pm standard deviation (SD). Categorical data are given as the number (percentage). Continuous variables were

compared using a paired or unpaired t test or Wilcoxon rank sum test, as appropriate. Categorical variables were analyzed using a 2 -sided chi-square or Fischer exact test, as appropriate. For analysis of variance (ANOVA), Welch's test for unequal sample sizes was used. The threshold of statistical significance was $p < 0.05$. Statistical analyses were performed using SAS software (version 9.4; SAS Institute, USA) and STATSOFT software for Welch's test (Statistica, version 10, USA).

RESULTS

Anatomy

The presence of acute or subacute supratibial arterial occlusions was documented in 314 (99.4 %) of 316 patients with threatened lower limbs due to ALI and SLI. Mean length of supratibial occlusion was greater in group with ALI (244.6 mm) vs. SLI (202.0 mm), $p=0.0159$ and in patients with thrombotic cause of the occlusion (246.6 mm) vs. embolism (155.0 mm, $p<.0001$).

The most frequently occluded (acutely or subacutely) locations were the femoropopliteal segment (in 73.1 % of 316 patients) and femoropopliteal bypass (22.8%). Significant difference in frequency of femoropopliteal segment and femoropopliteal bypass occlusion was not documented between patients with ALI vs. SLI and ALI IIB vs. ALI IIA (Table 1).

The aortoiliac segment occlusion was detected in 11.1 % of all patients, with higher incidence in those with ALI (13.9 %) vs. SLI (6.1 %, $p=.0401$) (Table 2). The incidence of the deep femoral artery occlusion was higher in patients with ALI vs. SLI (12.9 vs. 5.3 %, $p=0.0332$), embolism vs. thrombosis (23.3 vs. 7.0 %, $p=.0006$) and females vs. males (15.2 vs. 6.5%, $p=.0142$) (Table 2).

Infrapopliteal occlusion (acute or subacute) additional to occlusion located supratibially was documented in 61.7 % of all patients (ALI + SLI) with higher frequency in patients with ALI (68.3 %) vs. SLI (50.0 %, $p=.0017$), ALI IIB (72.6 %) vs. ALI IIA (57.1 %, $p=.0427$) and embolism (73.3 %) vs. thrombosis (59.0 %, $p=.0403$) (Table 2, 4, 6).

Infrapopliteal occlusion (acute, subacute and chronic; segmental or total) in one, two or three tibial vessels was detected in 86.1 % of 316 patients with significant difference between ALI (90.6 %) vs. SLI (78.1 %, $p=.0036$) subjects. All tibial vessels occluded were documented in 33.3 % of SLI and 62.4 % of ALI patients ($p=.0001$) (Fig. 1).

Higher mean number of patent (without acute, subacute or chronic occlusions) tibial vessels was detected in patients with SLI (1.3) vs. ALI (0.7, $p<.0001$), ALI IIA (1.4) vs. ALI IIB (0.4, $p<.0001$), thrombosis (1.0) vs. embolism (0.4, $p<.0001$) (Table 2, 4, 6).

Higher incidence of the femoropopliteal segment occlusion was established in subjects with embolism (95.0 %) vs. thrombosis (68.0 %, $p<.0001$) and in female group (79.5 %) vs. males (68.5 %, $p=.0296$).

Higher frequency of the femoropopliteal bypass occlusion was detected in the male group (28.8 %) vs. females (14.4 %, $p=.0027$) and patients with thrombotic occlusion (27.7 %) vs. embolism (1.7 %, $p<.0001$) (Table 6, 7).

Ankle-brachial index

Generally, the mean ABI was low (0.1) in the group of patients with ALI and SLI before treatment. Its value was higher in patients with SLI (0.22) vs. those with ALI (0.08, $p<.0001$), in subjects with ALI IIA (0.2) vs. ALI IIB (0.0, $p<.0001$) and in patients with thrombosis (0.14) vs. embolism (0.07, $p=.0016$) (Table 2, 4, 6). In subgroup with ABI ranged from 0.0 to 0.1, the patients with ALI were in majority (71.2 %). Patients with SLI dominated in the subgroups with ABI value from 0.2-0.5 (Fig 2).

The value of ABI significantly correlated ($p<.001$) with the number of patent calf vessels in subjects with ALI or SLI (Fig. 3,4).

Target occlusion origin: embolism vs. thrombosis

Embolism as the cause of target supratibial occlusion was detected in 19 % of patients with ALI+SLI. This cause was more frequent in patients with ALI (24.8 %) vs. SLI ((8.8 %, $p=.0005$), ALI IIB (28.8%) vs. ALI IIA (14.3 %, $p=.0442$) and in females (29.5 %) vs. males (11.4 %, $p<.0001$) (Table 2, 3, 7).

In comparison with thrombotic lesions, the embolic occlusions were shorter in average (155 vs. 246.6 mm, $p<.0001$) and they were localized more frequently in the femoropopliteal segment (95.0 vs. 68.0 %, $p<.0001$) and/or the deep femoral artery (23.3 vs. 7.0 %, $p=.0006$) (Table 6).

In patients with embolic supratibial closure, higher number (73.3 vs. 59.0 %, $p=.0403$) of those with additional occlusions (acute, subacute, chronic; embolic or thrombotic) located infrapopliteally was detected. Additionally, these subjects presented lower number of patent calf vessels (0.4 vs. 1.0, $p<.0001$) and lower ABI (0.07 vs. 0.14, $p=.0016$).

Embolism was also associated with higher age (73.7 vs. 70.2 years, $p=.0054$), higher incidence of female gender (65.0 % vs. 36.3 %, $p<.0001$), cardiac disease (61.7 vs. 37.5 %, $p=.0008$), arrhythmias (51.7 vs. 19.5 %, $p<.0001$), ALI (83.3 vs. 59.4 %, $p=.0005$) and ALI IIB (84.0 vs. 68.4 %, $p=.0442$).

On the other hand, patients with thrombotic occlusion presented more frequent male gender (63.7 vs. 35 %, $p<.0001$), positive smoking history (59.8 vs. 31.7 %, $p<.0001$), SLI (40.6 vs. 16.7 %, $p=.0005$), ALI IIA (31.6 vs. 16 %, $p=.0442$), claudication (32.4 vs. 15 %, $p=.0071$), critical limb ischaemia (26.6 vs. 10 %, $p=.0062$), tissue defect (17.2 vs. 5 %, $p=.0151$), in-stent occlusion (27.7 vs. 5 %, $p<.0001$), femoropopliteal bypass occlusion (27.1

vs. 1.7 %, $p<.0001$) higher number of patent calf vessels (1.0 vs. 0.4, $p<.0001$) and higher ABI (0.14 vs. 0.07, $p=.0016$) (Table 5,6).

Risk factors and concomitant disease

Comparison between patients with SLI and ALI detected significantly higher frequency of the smoking history (64.0 vs. 49.0 %, $p=.0134$), claudication (53.5 vs. 15.3 %, $p<.0001$) and tissue defect (22.8 vs. 10.4 %, $p=.0047$). The ALI patients were older (mean age: 72.6 vs. 67.9 years, $p=.0005$), with longer target lesion (mean length: 244.6 vs. 202.0 mm, $p=.0159$), higher frequency of rest pain (83.7 vs. 57.9 %, $p<.0001$), embolism (24.8 vs. 8.8 %, $p=.0005$), arrhythmias (30.7 vs. 16.7 %, $p=.0071$). A higher statistical trend toward increased incidence of cardiac disease (46.0 vs. 35.1 %, $p=.0749$), cerebrovascular disease (28.2 vs. 19.3 %, $p=.0809$) and renal insufficiency (26.7 vs. 17.5 %, $p=.0726$) was detected in ALI subjects (Table 1,2).

Comparison between ALI patients with immediately (IIB) and marginally (IIA) threatened extremities detected significantly higher frequency of diabetes (36.3 vs. 21.4 %, $p=.0452$), rest pain (91.8 vs. 62.5 %, $p<.0001$), embolism (28.8 vs. 14.3 %, $p=.0442$) in II B subjects, together with lower mean number of patent calf vessels (0.4 ± 0.9 vs. 1.4 ± 1.1 , $p<.0001$), ankle-brachial index (0.0 ± 0.1 vs. 0.2 ± 0.2 , $p<.0001$) and shorter mean duration of the ischaemic symptoms (3.1 vs. 6.8 days, $p=.0004$). Patients with ALI IIB also presented higher incidence of the cerebrovascular disease (32.2 vs. 17.9 %, $p=.0543$) and the renal insufficiency (26.7 vs. 17.5 %, $p=.0726$), but those differences were beyond the statistical significance (Table 3,4).

Subjects with ALI IIA presented higher frequency of smoking history (60.7 vs. 44.5 %, $p=.0425$), hyperlipidaemia (50.0 vs. 32.9 %, $p=.0344$), claudication (39.3 vs. 6.2 %, $p=.0425$), hyperlipidaemia (50.0 vs. 32.9 %, $p=.0344$), claudication (39.3 vs. 6.2 %, $p=.0425$), hyperlipidaemia (50.0 vs. 32.9 %, $p=.0344$), claudication (39.3 vs. 6.2 %, $p=.0425$).

p<.0001) and thrombosis (85.7 vs. 71.2 %, p=.0442+) as the cause of target occlusion (Table 3, 4).

Gender: Females vs. males

Female gender was associated with higher mean age (75.1 vs. 67.9 years, p<.0001), higher incidence of hypertension (81.1 vs. 70.1 %, p=.0355), arrhythmias (34.8 vs. 19.0 %, p=.0017) and embolism (29.5 vs. 11.4 %, p<.0001) as the cause of target arterial occlusion. Additionally, the occlusion was more frequently located in the femoropopliteal arterial segment (79.5 vs. 68.5 %, p=.0296) and the deep femoral artery (15.2 vs. 6.5 %, p=.0142) in this subgroup. Male subgroup presented more frequent smoking history (67.4 vs. 36.4 %, p<.0001), renal insufficiency (27.7 vs. 17.4 %, p=.0429), tissue defect (18.5 vs. 9.8 %, p=.0375), thrombotic cause of the occlusion (88.6 vs. 70.5 %, p<.0001) and femoropopliteal bypass occlusion (28.8 vs. 14.4 %, p=.0027). A higher statistical trend in favour of claudication (33.2 vs. 23.5 %, p=.0785) was also detected in this subgroup (Table 7).

Clinical presentation

Comparison between ALI patients with immediately (IIB) and marginally (IIA) threatened extremities detected significantly shorter mean duration of the ischaemic symptoms (3.1 vs. 6.8 days, p=.0004). The incidence of tissue defects was higher in males (18.5 % vs. 9.8 %, p=.0375), SLI vs. ALI (22.8 vs 10.4 %, p=.0047), patients with thrombosis vs. embolism (17.2 vs. 5.0 %, p=.0151). The rest pain occurred more frequently in ALI group (83.7 % vs. 57.9 %, p<.0001), and in ALI IIB vs. ALI IIA (91.8 vs. 62.5 %, p<.0001). The claudication was detected in 53.5 % of subjects with SLI (vs. 15.3 % in ALI, p<.0001), 39.3 % of ALI IIA (vs. 6.2 % in ALI IIB, p<.0001) and in patients with thrombosis (32.4 %) vs. embolism (15.0 %, p=.0071) (Table 1,3,5,7).

DISCUSSION

Ischaemia severity, symptoms duration and their progression in time vary with the grade and dynamics of blood flow deterioration. Vessel anatomy before ALI attack, site and cause of acute arterial occlusion, collateral development, embolus fragmentation and its displacement to the peripheral branches, thrombosis progression, runoff quality and antithrombotic therapy are the factors influencing clinical presentation of ALI. Together with serious comorbidities, they affect periprocedural, early and long-term treatment outcomes, morbidity, mortality and amputation rates. Detailed angiography description and pre-treatment ABI data were often not presented in the study reports dedicated to surgical and/or endovascular therapy of ALI. Thus, the correlation of ischaemic symptoms and their duration with the limb hemodynamics and vascular anatomy is difficult or impossible from the literature.

In retrospective analysis of 160 ALI patients (symptoms duration 7 days or less, 13 % embolic and 87 % thrombotic occlusions, 75 % clinical category II) managed with 186 intraarterial thrombolytic procedures, McNamara and colleagues¹² correlated angiographic patterns with clinical severity of ischemia. They based the angiographic categorization on the number of occluded arterial segments (common iliac, external iliac, common femoral, superficial femoral, popliteal, trifurcation, bypass grafts), presence of visible patent distal vessels, existence of patent collateral vessels, and the occurrence of stenoses involving inflow, collateral, or outflow vessels. Clinical category “viable“ (I) correlated with single-segment occlusion, patent collaterals and distal vessels. Patients requiring blood to flow through two contiguous collateral beds to supply distal vessels or with single occlusion combined with stenosis of the adjacent inflow, outflow or collateral vessel correlated with the clinical category “threatened“ (II). Occlusions of more than two segments with distal propagation that occluded the distal vascular bed correlated with the clinical category “irreversible“ (III).

295 Severity of ischemia and extent of the occlusion correlated with death and amputation rate at
296 30 days.

297 In their study of 45 patients with embolic occlusions managed by thrombolysis, Huettl
298 and Soulen¹³ detected no patent calf vessels in 56 % of patients, one calf vessel was patent in
299 22 %, two in 7 % and three in 16 % of patients before treatment. Those numbers are close to
300 our data. Using thrombolysis and additional endovascular techniques for treatment of non-
301 embolic ALI in 119 patients (72 % grafts, 68 % category I), Kashyap and associates¹⁴
302 detected multisegmental thrombosis in 16 % and tibial thrombosis in 22 % of patients. Distal
303 occlusions beyond the reach of the rheolytic catheter limited the treatment in 57 % of 86
304 patients with ALI or SLI in the study of Kasirajan et al¹⁵. The need for distal thrombectomy
305 and poor intra-operative runoff were detected among risk factors for amputation and death in
306 107 patients with ALI undergoing infrainguinal bypass¹⁶. Also, any patent pedal outflow was
307 a significant predictor for technical success in patients with ALI managed surgically (296 pts)
308 or by endovascular technique (147 pts) in the study of Taha and associates¹⁷. Failed
309 mechanical recanalization of the diffusely occluded infrapopliteal vascular bed influenced the
310 need for thrombolytic therapy, the rate of major bleeding, treatment outcomes, amputation
311 and mortality rates in patients with ALI and SLI⁸.

312 The greatest mean lesion lengths were reported in the studies of ALI and SLI patients
313 with target occlusions located in the femoropopliteal bypass (32.1; 28.4 cm)^{18,19}. In our series,
314 the mean length of the target occlusion was 22.9 cm and 22.8 % of 316 patients suffered from
315 occluded femoropopliteal bypass.

316 The comparison between patients with embolic vs. thrombotic cause of arterial
317 occlusions, we documented higher age, higher frequency of female gender, cardiac disease,
318 arrhythmias, ALI, ALI IIB, occlusions of femoropopliteal segment and/or profunda femoris in
319 subjects with embolism. They also presented higher frequency of additional infrapopliteal

occlusion, lower number of patent tibial vessels and lower ABI before treatment. Thus, historical view that embolism produces more severe ischaemia than thrombosis was confirmed.

Thrombosis subgroup presented higher incidence of male gender, smoking history, subacute ischemia, acute ischemia IIA, claudication, tissue defect, femoropopliteal bypass and in-stent occlusions. Furthermore, these patients presented greater mean occlusion length, higher ABI and number of patent calf vessels. Aune and Trippestad²⁰ reported in their study of 272 patients managed by embolectomy (192 pts. with embolism) or bypass (80 pts. with thrombosis), a higher mean age, frequency of female gender and cardiac disease, together with shorter life expectancy in patients with embolism. Kuukasjarvi et al. in their study of 509 ALI patients (without previous reconstructions) from National Vascular Registry²¹ detected higher frequency of embolism in patients of age 75 or more years and smoking as a risk factor for acute thrombosis. The authors speculated that the worse prognosis (higher amputation rate, mortality rates and necessity for repeated interventions) of patients with acute thrombotic occlusion was associated with advanced atherosclerosis.

Higher age and frequency of hypertension, arrhythmias, embolism, occlusions of femoropopliteal segment and deep femoral artery were associated with female gender. Smoking history, renal insufficiency, tissue defects, thrombosis as a cause of the occlusion and femoropopliteal bypass occlusion were more frequent in patients of male gender. Additionally, we observed statistical trend toward more frequent claudication in the male group.

Similar results can be found in the literature. Braithwaite and colleagues²² managed 84 elderly patients (75-100 years) with ALI by surgery and/or thrombolysis. Percentage of females was 71.4 % in their series and female preponderance was greatest (84.8 %) in the subgroup selected for immediate embolectomy. Female predominance was detected also in

other studies: 57 % in subgroup with embolism¹⁸ and 54 % of 23 268 ALI patients of the National Inpatient Sample (NIS)²³. Kashyap and associates¹⁴ reported increased risk of limb loss with the female gender in 119 ALI patients managed by thrombolysis. Mortality rate was 6 % and dying patients were women only. Female gender as a risk associated with limb amputation was detected also by Kuoppala M and colleagues²⁴. The NATALI study²⁵ described female gender as a risk factor for mortality and for all and major complications associated with thrombolytic treatment. On the other hand, Eliason JL et al.²³ reported decreased risk of amputation in women, in patients with embolectomy, percutaneous transluminal angioplasty and age less than 63 years in NIS patients. The authors did not detect the female preponderance or lower amputation risk in their single institution study (105 patients).

CONCLUSION:

Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The value of ABI related to the number of occluded tibial arteries.

The most frequent locations of supratibial occlusions were femoropopliteal segment (73.1 %) and femoropopliteal bypass (22.8 %) without significant difference in clinical categories. Occlusion locations related to ALI (IIA+IIB) were the aortoiliac segment and/or profunda femoris. Also, more ALI subjects presented additional infrapopliteal occlusion (acute and/or subacute) and lower number of patent tibial arteries and lower ABI.

Anatomically, the important factor related to the ischaemia severity and symptoms duration was the status of infrapopliteal vascular bed. The number of patent or acutely, subacutely and chronically occluded tibial vessels related to individual clinical categories of ALI and SLI and to ABI. This suggests that tibial reperfusion can be essential for the salvage of threatened limb and should be always considered.

Patients with the most severe ischaemia and immediately threatened extremity (ALI IIB) presented shortest symptoms duration, higher frequency of rest pain, embolism, diabetes, additional acute infrapopliteal occlusion, lower number of patent tibial vessels and lower ABI in comparison with ALI IIA patients. More frequent diabetes can participate on higher number of occluded tibial vessels in this subgroup.

On the other hand, more patients with thrombosis, smoking history, hyperlipidemia, claudication, higher number of patent calf vessels and higher ABI were detected in ALI IIA subgroup.

In comparison with ALI group, the subjects with SLI presented more frequently the thrombosis as a cause of target occlusion, smoking history, claudication, tissue defects, shorter target occlusion, lower number of occluded tibial vessels and higher ABI. Furthermore, they presented younger age, less embolism and arrhythmias, less aortoiliac segment and deep femoral artery occlusions.

Embolism as a cause of the supratibial arterial occlusion was associated with higher age, female gender, cardiac disease, arrhythmias, ALI, ALI IIB, femoropopliteal segment and deep femoral artery occlusions, infrapopliteal occlusions, lower ABI and number of patent calf vessels. Higher ischaemia severity in subjects with embolism was not associated only with the fact that embolus suddenly occluded healthy supratibial artery but also with higher frequency of additional infrapopliteal occlusion, profunda femoris occlusion and the higher number of occluded tibial vessels. The data confirmed a historical view that the most severe ischemia occurs with the embolism.

Thrombosis was associated with smoking history, SLI, ALI IIA, claudication, tissue defects, longer target lesion, femoropopliteal bypass occlusion, in-stent occlusion, higher ABI and number of patent calf vessels.

Patients of female gender presented higher age, higher frequency of hypertension, arrhythmias, embolism, femoropopliteal and profunda femoris occlusions. Male group manifested a higher frequency of smoking history, renal insufficiency, tissue defect, thrombosis and femoropopliteal bypass occlusion.


Grouping the patients categorized in different clinical categories of ALI and SLI can affect the treatment outcomes.

REFERENCES

1. Norgren L, Hiatt WR, Dormandy JA et al. Inter-society consensus for the management of peripheral arterial diseases (TASC II). *Eur J Vasc Endovasc Surg* 2007;33, suppl 1:S1-S75.
2. Rutherford RB, Baker JD, Ernst C et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version. *J Vasc Surg* 1997;26:517-538.
3. Patel N, Sacks D, Patel RI et al. SCVIR reporting standards for the treatment of acute limb ischemia with use of transluminal removal of arterial thrombus. *J Vasc Interv Radiol* 2001;12:559-570.
4. Karnabatidis D, Spiliopoulos S, Tsetis D, Siablis D. Quality improvement guidelines for percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for acute lower-limb ischemia. *Cardiovasc Intervent Radiol* 2011;34:1123-1136.
5. Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. *Surgery* 1998;124:336-342.
6. Henke PK. Contemporary management of acute limb ischemia: factors associated with amputation and in-hospital mortality. *Semin Vasc Surg* 2009;22:34-40.
7. Dosluoglu HH, Harris LM. Endovascular management of subacute lower extremity ischemia. *Semin Vasc Surg* 2008;21:167-179.
8. Bulvas M, Sommerová Z, Vaněk I, Weiss J. Prospective single-arm trial of endovascular mechanical debulking as initial therapy in patients with acute and subacute lower limb ischemia: one-year outcomes. *J Endovasc Ther* 2019;26:291-301.
9. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary. A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol* 2006;47:1239-1312.


10. Tendera M, Aboyans V, Bartelink ML, et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2011;32:2851–2906.
11. O’Connell JB, Quiñones-Baldrich WJ. Proper evaluation and management of acute embolic versus thrombotic limb ischemia. *Semin Vasc Surg* 2009;22:10-16.
12. McNamara TO, Gardner KR, Bomberger RA, Greaser LE. Clinical and angiographic selection factors for thrombolysis as initial therapy for acute lower limb ischemia. *J Vasc Interv Radiol* 1995;6(suppl):36S-47S.
13. Huettl EA, Soulen MC. Thrombolysis of lower extremity embolic occlusions: a study of the results of the Star Registry. *Radiology* 1995;197:141-145.
14. Kashyap VS, Gilani R, Bena JF, Bannazadeh M, Sarac TP. Endovascular therapy for acute limb ischemia. *J Vasc Surg* 2011;53:340-46.
15. Kasirajan K, Gray B, Beavers FP, Clair DG, Greenberg R, Mascha E, Ouriel K. Rheolytic thrombectomy in the management of acute and subacute limb-threatening ischemia. *J Vasc Interv Radiol* 2001; 12:413–421.
16. Marqués de Marino P, Martínez López I, Revuelta Suero S et al. Results of infrainguinal bypass in acute limb ischaemia. *Eur J Vasc Endovasc Surg* 2016;51:824-30.
17. Taha AG, Byrne RM, Avgerinos ED, Marone LK et al. Comparative effectiveness of endovascular versus surgical revascularization for acute lower extremity ischemia *J Vasc Surg* 2015;61:147-54.
18. Hundt W, Kalinowski M, Stamm AC, Portig I, Swaid Z, Dietz C, Geks J, Burbelko M. Combined treatment of subacute and acute synthetic and venous bypass-graft occlusions with percutaneous mechanical thrombectomy and thrombolysis. *Eur J Radiol* 2013;82:e807– e815. doi: 10.1016/j.ejrad.2013.08.016
19. Wissgott C, Kamusella P, Andresen R. Recanalization of acute and subacute venous and synthetic bypass-graft occlusions with a mechanical rotational catheter. *Cardiovasc Intervent Radiol* 2013;36:936–942.
20. Aune S, Trippstad A. Operative mortality and long-term survival of patients operated on for acute lower limb ischaemia. *Eur J Vasc Endovasc Surg* 1998;15:143-146.
21. Kuukasjarvi P, Salenius J.P and the Finnvasc study group. Perioperative outcome of acute lower limb ischaemia on the basis of the National Vascular Registry. *Eur J Vasc Surg* 1994;8:578-583.
22. Braithwaite BD, Davies B, Birch PA, Heather BP, Earnshaw JJ. Management of acute leg ischaemia in the elderly. *Brit J Surg* 1998;85:217-220.

- 480 23. Eliason JL, Wainess RM, Proctor MC, Dimick JB, Cowan JA et al. A National and single
481 institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann
482 Surg 2003;238:382-390.
- 483 24. Kuoppala M, Franzén S, Lindblad B, Acosta S. Long-term prognostic factors after
484 thrombolysis for lower limb ischemia. J Vasc Surg 2008;47:1243-1250.
- 485 25. Earnshaw JJ, Whitman B, Foy C for the Thrombolysis Study Group. National Audit of
486 Thrombolysis for Acute Leg Ischemia (NATALI): Clinical factors associated with early
487 outcome. J Vasc Surg 2004;39:1018-25.
- 488
- 489




Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
Number of patent calf vessels before treatment	n Mean \pm SD	316 0.9 \pm 1.1	114 1.3 \pm 1.2	202 0.7 \pm 1.0	<.0001
Patients with no patent tibial vessels	% (n/N)	51.9% (164/316)	33.3% (38/114)	62.4% (126/202)	0.0001
Patients with 1 patent tibial vessel	% (n/N)	17.7% (56/316)	22.8% (26/114)	14.9% (30/202)	0.0914
Patients with 2 patent tibial vessels	% (n/N)	16.5% (52/316)	21.9% (25/114)	13.4% (27/202)	0.0581
Patients with 3 patent tibial vessels	% (n/N)	13.9% (44/316)	21.9% (25/114)	9.4% (19/202)	0.0036

Fig. 1. ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD - standard deviation, vss-vessel(s)




Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
ABI before treatment	n Mean ± SD	309 0.1 ± 0.2	108 0.2 ± 0.2	201 0.1 ± 0.1	<.0001
ABI 0-0.1	% (n/N)	57% (176/309)	31.4% (34/108)	71.2% (143/201)	<.0001
ABI 0.11-0.2	% (n/N)	8.7% (27/309)	7.6% (8/108)	9.0% (18/201)	0.8302
ABI 0.21-0.3	% (n/N)	14.2% (44/309)	25.7% (28/108)	8.5% (17/201)	0.0001
ABI 0.31-0.4	% (n/N)	13.9% (43/309)	23.8% (26/108)	8.0% (16/201)	0.0002
ABI 0.41-0.5	% (n/N)	4.5% (14/309)	8.6% (9/108)	2.5% (5/201)	0.0236
ABI 0.51-0.6	% (n/N)	1.3% (4/309)	2.8% (3/108)	0.5% (1/201)	0.1245
ABI 0.61-0.7	% (n/N)	0.3% (1/309)	0% (0/108)	0.5% (1/201)	

Fig. 2. Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 – 0.5), SLI is more frequent.



Breakdown Table of Descriptive Statistics (tibial vessels patent, ABI)					
Welch ANOVA test ($p < 0.001$)					
SLI tibial vessels patent	ABI SLI Means	ABI SLI N	ABI SLI SD	ABI SLI Minimum	ABI SLI Maximum
0	0.139	37	0.160	0	0.420
1	0.214	21	0.129	0	0.450
2	0.244	25	0.156	0	0.460
3	0.346	24	0.150	0	0.600
All Groups	0.229	107	0.168	0	0.600

Fig. 3. The number of patent tibial vessels significantly ($p < .001$) correlates to ABI in SLI patients .



Breakdown Table of Descriptive Statistics (tibial vessels patent, ABI)					
Welch ANOVA test ($p < 0.001$)					
ALI tibial vessels patent	ABI ALI Means	ABI ALI N	ABI ALI SD	ABI ALI Minimum	ABI ALI Maximum
0	0.032	125	0.090	0	0.460
1	0.150	30	0.165	0	0.460
2	0.151	27	0.173	0	0.560
3	0.149	19	0.176	0	0.620
All Groups	0.081	201	0.140	0	0.620

Fig. 4. Also in ALI patients, the number of patent tibial vessels significantly ($p < 0.001$) correlates to ABI.

LEGENDS

Fig. 1. ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD - standard deviation, vss-vessel(s)

Fig. 2. Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 – 0.5), SLI is more frequent.

Fig. 3. The number of patent tibial vessels significantly ($p<.001$) correlates to ABI in SLI patients.

Fig. 4. Also in ALI patients, the number of patent tibial vessels significantly ($p<.001$) correlates to ABI.

Table 1. Demography, concomitant disease, ischemia classification and symptoms: SLI vs. ALI

Table 2. Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI

Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB

Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB

Table 5. Demographics, concomitant disease, ischemia classification and symptoms: thrombosis vs. embolism

Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism

Table 7. Age, concomitant disease, symptoms, ischemia classification, occlusion length and location: female vs. male gender

Table 1. Demography, concomitant disease, ischaemia classification and symptoms: SLI vs. ALI

Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
Age (years)	n Mean \pm SD Median Range	316 70.9 \pm 12.0 71.0 23.0, 96.0	114 67.9 \pm 10.9 67.0 31.0, 94.0	202 72.6 \pm 12.2 73.0 23.0, 96.0	0.0005
Male	% (n/N)	58.2% (184/316)	61.4% (70/114)	56.4% (114/202)	0.4079
Diabetes	% (n/N)	30.7% (97/316)	28.1% (32/114)	32.2% (65/202)	0.5256
Smoking history	% (n/N)	54.4% (172/316)	64.0% (73/114)	49.0% (99/202)	0.0134
Hyperlipidaemia	% (n/N)	38.9% (123/316)	41.2% (47/114)	37.6% (76/202)	0.5496
Hypertension	% (n/N)	74.7% (236/316)	73.7% (84/114)	75.2% (152/202)	0.7884
Cardiac disease	% (n/N)	42.1% (133/316)	35.1% (40/114)	46.0% (93/202)	0.0749
Arrhythmias	% (n/N)	25.6% (81/316)	16.7% (19/114)	30.7% (62/202)	0.0071
Cerebrovascular disease	% (n/N)	25.0% (79/316)	19.3% (22/114)	28.2% (57/202)	0.0809
Malignant disease	% (n/N)	7.3% (23/316)	7.9% (9/114)	6.9% (14/202)	0.8226
Renal insufficiency	% (n/N)	23.4 % (74/316)	17.5 % (20/114)	26.7 % (54/202)	0.0726
Acute limb ischaemia category IIA	% (n/N)	17.7% (56/316)		27.7% (56/202)	
Acute limb ischaemia category IIB	% (n/N)	46.2% (146/316)		72.3% (146/202)	
Subacute limb ischaemia	% (n/N)	36.1% (114/316)	100% (114/114)		
Symptoms duration	days	70.9 \pm 12.0	44.3 \pm 27.3	4.13 \pm 4.47	<.0001
Claudication	% (n/N)	29.1% (92/316)	53.5% (61/114)	15.3% (31/202)	<.0001
Rest pain	% (n/N)	74.4% (235/316)	57.9% (66/114)	83.7% (169/202)	<.0001
Tissue defect	% (n/N)	14.9% (47/316)	22.8% (26/114)	10.4% (21/202)	0.0047

Table 2 Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI

Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
Target occlusion length (mm)	n Mean ± SD Median Range	316 229.2 ± 148.1 200.0 15.0, 650.0	114 202.0 ± 136.7 150.0 15.0, 650.0	202 244.6 ± 152.4 200.0 20.0, 590.0	0.0159
Target occlusion cause: Embolism	% (n/N)	19.0% (60/316)	8.8% (10/114)	24.8% (50/202)	0.0005
Target occlusion cause: Thrombosis	% (n/N)	81.0% (256/316)	91.2% (104/114)	75.2% (152/202)	0.0005
Aortoiliac segment occlusion	% (n/N)	11.1% (35/316)	6.1% (7/114)	13.9% (28/202)	0.0401
Femoropopliteal segment occlusion	% (n/N)	73.1% (231/316)	78.9% (90/114)	69.8% (141/202)	0.0868
Femoropopliteal bypass occlusion	% (n/N)	22.8% (72/316)	17.5% (20/114)	25.7% (52/202)	0.1241
Femoro-femoral cross bypass occlusion	% (n/N)	0.6% (2/316)	0	1.0% (2/202)	0.5373
Leg of bifurcation stentgraft occlusion	% (n/N)	0.3% (1/316)	0	0.5% (1/202)	1.0000
Ileofemoral bypass occlusion	% (n/N)	0.3% (1/316)	0.9% (1/114)	0	0.3608
Deep femoral artery occlusion	% (n/N)	10.1% (32/316)	5.3% (6/114)	12.9% (26/202)	0.0332
In-stent occlusion	% (n/N)	23.4% (74/316)	21.9% (24/114)	24.3% (49/202)	0.6800
Additional infrapopliteal occlusion	% (n/N)	61.7% (195/316)	50.0% (57/114)	68.3% (138/202)	0.0017
Number of patent calf vessels before treatment	n Mean ± SD Median Range	316 0.9 ± 1.1 0.0 0.0, 4.0	114 1.3 ± 1.2 1.0 0.0, 3.0	202 0.7 ± 1.0 0.0 0.0, 4.0	<.0001
ABI before treatment	n Mean ± SD Median Range	309 0.1 ± 0.2 0.0 0.0, 0.6	108 0.2 ± 0.2 0.3 0.0, 0.6	201 0.1 ± 0.1 0.0 0.0, 0.6	<.0001

Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB.

Characteristics	Summary Statistics	All ALI Subjects	ALI IIA	ALI IIB	p-value
Age (years)	n Mean \pm SD Median Range	202 72.6 \pm 12.2 73.0 23.0, 96.0	56 70.8 \pm 12.9 73.0 23.0, 96.0	146 73.2 \pm 11.9 74.0 43.0, 96.0	0.2113
Male	% (n/N)	56.4% (114/202)	62.5% (35/56)	54.1% (79/146)	0.4079
Diabetes	% (n/N)	32.2% (65/202)	21.4% (12/56)	36.3% (53/146)	0.0452
Smoking history	% (n/N)	49.0% (99/202)	60.7% (34/56)	44.5% (65/146)	0.0425
Hyperlipidaemia	% (n/N)	37.6% (76/202)	50.0% (28/56)	32.9% (48/146)	0.0344
Hypertension	% (n/N)	75.2% (152/202)	71.4% (40/56)	76.7% (112/146)	0.4685
Cardiac disease	% (n/N)	46.0% (93/202)	41.1% (23/56)	47.9% (70/146)	0.4319
Arrhythmias	% (n/N)	30.7% (62/202)	28.6% (16/56)	31.5% (46/146)	0.7357
Cerebrovascular disease	% (n/N)	28.2% (57/202)	17.9% (10/56)	32.2% (47/146)	0.0543
Malignant disease	% (n/N)	6.9% (14/202)	5.4% (3/56)	7.5% (11/146)	0.7615
Renal insufficiency	% (n/N)	23.4% (74/316)	17.5% (20/114)	26.7% (54/202)	0.0726
Symptoms duration (days)	n Mean \pm SD Median Range	202 4.1 \pm 4.5 2.0 0.04, 14.0	56 6.8 \pm 5.3 6.5 0.08, 14.0	146 3.1 \pm 3.6 2.0 0.04, 14.0	0.0004
Claudication	% (n/N)	15.3% (31/202)	39.3% (22/56)	6.2% (9/146)	<.0001
	% (n/N)				
Rest pain	% (n/N)	83.7% (169/202)	62.5% (35/56)	91.8% (134/146)	<.0001
Tissue defect	% (n/N)	10.4% (21/202)	10.7% (6/56)	10.3% (15/146)	1.000
Target occlusion cause: Embolism	% (n/N)	24.8% (50/202)	14.3% (8/56)	28.8% (42/146)	0.0442
Target occlusion cause: Thrombosis	% (n/N)	75.2% (152/202)	85.7% (48/56)	71.2% (104/146)	0.0442

Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB

Characteristics	Summary Statistics	All Subjects	ALI IIA	ALI IIB	p-value
Target occlusion length (mm)	n Mean ± SD Median Range	202 244.6 ± 152.4 200.0 20.0, 590.0	56 215.5 ± 150.2 150.0 20.0, 550.0	146 255.7 ± 152.3 220.0 20.0, 590.0	0.0938
Aortoiliac segment occlusion	% (n/N)	13.9 % (28/202)	14.3 % (8/56)	13.7 % (20/146)	1.000
Femoropopliteal segment occlusion	% (n/N)	69.8% (141/202)	69.6% (39/56)	69.9% (102/146)	1.000
Femoropopliteal bypass	% (n/N)	25.7 % (52/202)	25.0 % (14/56)	26.0 % (38/146)	1.000
Leg of bifurcation stentgraft occlusion	% (n/N)	0.5% (1/202)	1.8% (1/56)	0.5% (1/202)	0.2772
Ileofemoral bypass occlusion	% (n/N)	25.7% (52/202)	25.0% (14/56)	26.0% (38/146)	1.000
Deep femoral artery occlusion	% (n/N)	12.9% (26/202)	5.4% (3/56)	15.8% (23/146)	0.0597
In-stent occlusion	% (n/N)	24.3% (49/202)	33.9% (19/56)	20.5% (30/146)	0.0657
Additional infrapopliteal occlusion	% (n/N)	68.3% (138/202)	57.1% (32/56)	72.6% (106/146)	0.0427
No. of patent calf vessels before treatment	n Mean ± std Median Range	202 0.7 ± 1.0 0.0 0.0, 4.0	56 1.4 ± 1.1 1.0 0.0, 3.0	146 0.4 ± 0.9 0.0 0.0, 4.0	<.0001
ABI before treatment	n Mean ± SD Median Range	201 0.1 ± 0.1 0.0 0.0, 0.6	55 0.2 ± 0.2 0.2 0.0, 0.6	146 0.0 ± 0.1 0.0 0.0, 0.4	<.0001

Table 5. Demographics, concomitant disease, ischaemia classification and symptoms: thrombosis vs. embolism

Characteristics	Summary Statistics	All Subjects	Thrombosis	Embolism	p-value
Age (years)	n Mean \pm SD Median Range	316 70.9 \pm 12.0 71.0 23.0, 96.0	256 70.2 \pm 11.3 70.0 43.0, 96.0	60 73.7 \pm 14.2 76.0 23.0, 94.0	0.0054
Male	% (n/N)	58.2% (184/316)	63.7% (163/256)	35.0% (21/60)	<.0001
Female	% (n/N)	41.8% (132/316)	36.3% (93/256)	65.0% (39/60)	<.0001
Diabetes	% (n/N)	30.7% (97/316)	30.1% (77/256)	33.3% (20/60)	0.6425
Smoking history	% (n/N)	54.4% (172/316)	59.8% (153/256)	31.7% (19/60)	<.0001
Hyperlipidaemia	% (n/N)	38.9% (123/316)	39.5% (101/256)	36.7% (22/60)	0.7692
Hypertension	% (n/N)	74.7% (236/316)	74.6% (191/256)	75.0% (45/60)	1.0000
Cardiac disease	% (n/N)	42.1% (133/316)	37.5% (96/256)	61.7% (37/60)	0.0008
Arrhythmias	% (n/N)	25.6% (81/316)	19.5% (50/256)	51.7% (31/60)	<.0001
Cerebrovascular disease	% (n/N)	25.0% (79/316)	26.6% (68/256)	18.3% (11/60)	0.2458
Malignant disease	% (n/N)	7.3% (23/316)	7.8% (20/256)	5.0% (3/60)	0.5874
Renal insufficiency	% (n/N)	23.4% (74/316)	23.8% (61/256)	21.7% (13/60)	0.8657
Subacute ischaemia	% (n/N)	36.1% (114/316)	40.6% (104/256)	16.7% (10/60)	0.0005
Acute ischaemia	% (n/N)	63.9% (202/316)	59.4% (152/256)	83.3% (50/60)	0.0005
Acute ischaemia class IIA	% (n/N)	27.7% (56/202)	31.6% (48/152)	16.0% (8/50)	0.0442
Acute ischaemia class IIB	% (n/N)	72.3% (146/202)	68.4% (104/152)	84.0% (42/50)	0.0442
Claudication	% (n/N)	29.1% (92/316)	32.4% (83/256)	15.0% (9/60)	0.0071
Critical limb ischemia	% (n/N)	23.4% (74/316)	26.6% (68/256)	10.0% (6/60)	0.0062
Rest pain	% (n/N)	74.4% (235/316)	73.8% (189/256)	76.7% (46/60)	0.7436
Tissue defect	% (n/N)	14.9% (47/316)	17.2% (44/256)	5.0% (3/60)	0.0151

Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism

Characteristics	Summary Statistics	All Subjects	Thrombosis	Embolism	p-value
Target lesion length (mm)	n Mean ± SD Median Range	316 229.2 ± 148.1 200.0 15.0, 650.0	256 246.6 ± 150.4 220.0 15.0, 650.0	60 155.0 ± 111.7 125.0 20.0, 480.0	<.0001
Aortoiliac segment	% (n/N)	11.1% (35/316)	10.2% (26/256)	15.0% (9/60)	0.3588
Femoropopl segment	% (n/N)	73.1% (231/316)	68.0% (174/256)	95.0% (57/60)	<.0001
Femoropopl bypass	% (n/N)	22.8% (72/316)	27.7% (71/256)	1.7% (1/60)	<.0001
Femo-femoral cross bypass	% (n/N)	0.6% (2/316)	0.8% (2/256)		
Leg of bifurcation stentgraft	% (n/N)	0.3% (1/316)	0.4% (1/256)		
Ileofemoral bypass	% (n/N)	0.3% (1/316)	0.4% (1/256)		
Deep femoral artery	% (n/N)	10.1% (32/316)	7.0% (18/256)	23.3% (14/60)	0.0006
In-stent occlusion	% (n/N)	23.4% (74/316)	27.7% (71/256)	5.0% (3/60)	<.0001
Additional infrapopliteal occlusion	% (n/N)	61.7% (195/316)	59.0% (151/256)	73.3% (44/60)	0.0403
No. of patent calf vessels before treatment	n Mean ± SD Median Range	316 0.9 ± 1.1 0.0 0.0, 4.0	256 1.0 ± 1.1 1.0 0.0, 3.0	60 0.4 ± 0.9 0.0 0.0, 4.0	<.0001
ABI before treatment	n Mean ± SD Median Range	309 0.1 ± 0.2 0.0 0.0, 0.6	250 0.14 ± 0.17 0.0 0.0, 0.6	59 0.07 ± 0.14 0.0 0.0, 0.5	0.0016

Table 7. Age, concomitant disease, symptoms, ischaemia classification, occlusion length and location: female vs. male gender

Characteristics	Summary Statistics	All Subjects	Female	Male	p-value
Age (years)	n Mean \pm SD Median Range	316 70.9 \pm 12.0 71.0 23.0, 96.0	132 75.1 \pm 11.4 76.5 23.0, 96.0	184 67.9 \pm 11.5 67.5 31.0, 94.0	<.0001
Diabetes	% (n/N)	30.7% (97/316)	33.3% (44/132)	28.8% (53/184)	0.3903
Smoking history	% (n/N)	54.4% (172/316)	36.4% (48/132)	67.4% (124/184)	<.0001
Hyperlipidaemia	% (n/N)	38.9% (123/316)	41.7% (55/132)	37.0% (68/184)	0.4147
Hypertension	% (n/N)	74.7% (236/316)	81.1% (107/132)	70.1% (129/184)	0.0355
Cardiac disease	% (n/N)	42.1% (133/316)	42.4% (56/132)	41.8% (77/184)	1.0000
Arrhythmias	% (n/N)	25.6% (81/316)	34.8% (46/132)	19.0% (35/184)	0.0017
Cerebrovascular disease	% (n/N)	25.0% (79/316)	25.0% (33/132)	25.0% (46/184)	1.0000
Malignant disease	% (n/N)	7.3% (23/316)	6.8% (9/132)	7.6% (14/184)	0.8301
Renal insufficiency	% (n/N)	23.4% (74/316)	17.4% (23/132)	27.7% (51/184)	0.0429
Acute limb ischaemia category IIA	% (n/N)	27.7% (56/202)	23.9% (21/88)	30.7% (35/114)	0.3420
Acute limb ischaemia category IIB	% (n/N)	72.3% (146/202)	76.1% (67/88)	69.3% (79/114)	0.3420
Claudication	% (n/N)	29.1% (92/316)	23.5% (31/132)	33.2% (61/184)	0.0785
Critical limb ischaemia	% (n/N)	23.4% (74/316)	21.2% (28/132)	25.0% (46/184)	0.5011
Rest pain	% (n/N)	74.4% (235/316)	78.8% (104/132)	71.2% (131/184)	0.1509
Tissue defect	% (n/N)	14.9% (47/316)	9.8% (13/132)	18.5% (34/184)	0.0375
Target occlusion cause: Embolism	% (n/N)	19.0% (60/316)	29.5% (39/132)	11.4% (21/184)	<.0001
Target occlusion cause: Thrombosis	% (n/N)	81.0% (256/316)	70.5% (93/132)	88.6% (163/184)	<.0001
Target occlusion length (mm)	n Mean \pm SD Median Range	316 229.2 \pm 148.1 200.0 15.0, 650.0	132 221.0 \pm 142.1 200.0 20.0, 590.0	184 235.1 \pm 152.5 200.0 15.0, 650.0	0.5290
Aortoiliac segment	% (n/N)	11.1% (35/316)	14.4% (19/132)	8.7% (16/184)	0.1453
Femoropopliteal segment	% (n/N)	73.1% (231/316)	79.5% (105/132)	68.5% (126/184)	0.0296
Femoropopliteal bypass	% (n/N)	22.8% (72/316)	14.4% (19/132)	28.8% (53/184)	0.0027
Femo-femoral cross bypass	% (n/N)	0.6% (2/316)	0.8% (1/132)	0.5% (1/184)	1.0000
Leg of bifurcation stentgraft	% (n/N)	0.3% (1/316)		0.5% (1/184)	1.0000
Ileofemoral bypass	% (n/N)	0.3% (1/316)		0.5% (1/184)	1.0000
Deep femoral artery	% (n/N)	10.1% (32/316)	15.2% (20/132)	6.5% (12/184)	0.0142
In-stent occlusion	% (n/N)	23.4% (74/316)	24.2% (32/132)	22.8% (42/184)	0.7888
Additional infrapopliteal occlusion	% (n/N)	61.7% (195/316)	62.9% (83/132)	60.9% (112/184)	0.7266
Number of patent calf vessels	n Mean \pm SD Median Range	316 0.9 \pm 1.1 0.0 0.0, 3.0	132 0.9 \pm 1.1 0.0 0.0, 3.0	184 1.0 \pm 1.1 0.0 0.0, 3.0	0.6844
ABI before treatment	n Mean \pm SD Median Range	309 0.1 \pm 0.2 0.0 0.0, 0.6	129 0.12 \pm 0.16 0.0 0.0, 0.6	180 0.14 \pm 0.17 0.0 0.0, 0.6	0.2715